BiomX (PHGE) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
11 Mar, 2026Opening remarks and agenda
CEO and CFO, both newly appointed, welcomed shareholders and called the meeting to order.
Inspector of Election appointed and oath filed with meeting records.
Notice of meeting and proxy materials mailed to all stockholders of record.
Specific resolutions to be voted on
Approval of issuance of common stock underlying Series Y convertible preferred stock and warrants, as per agreements dated November and December 2025.
Approval of additional shares in excess of 19.99% of outstanding common stock due to voluntary adjustments.
Proposal to adjourn the meeting if more proxies are needed for approval.
Board and executive committee updates
CEO and CFO are both newly appointed and committed to advancing programs and disciplined execution.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BiomX
- Meeting adjourned and rescheduled due to lack of quorum; voting instructions remain valid.PHGE
EGM 202625 Feb 2026 - 2025 net loss reached $36.2M; cash burn and insolvency drive urgent need for new financing.PHGE
Q4 202519 Feb 2026 - Approval sought for major share issuance and potential meeting adjournment to secure votes.PHGE
Proxy Filing13 Feb 2026 - Registering 5.3M shares for resale may cause major dilution as focus shifts to phage therapies.PHGE
Registration Filing9 Feb 2026 - Approval sought for major stock issuance tied to recent $3M Private Placement and governance changes.PHGE
Proxy Filing3 Feb 2026 - $50M financing boosts pipeline, but losses and delisting risk require new capital by late 2025.PHGE
Q2 20241 Feb 2026 - Phage therapy advances with two Phase II programs and major clinical milestones expected in 2025.PHGE
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - BX211 phase II fully enrolled; BX004 phase II-B delayed; Q3 net income $9.6M, cash $24.7M.PHGE
Q3 202414 Jan 2026 - BX004 and BX211 show strong clinical progress, >$12M raised, and key data readouts ahead.PHGE
Q4 2024 & Study Result25 Dec 2025